XXXX : Current Concepts in Diagnosis, Staging and Treatment.

@entity1 @entity101 @entity96 @entity5 @entity648 @entity2857 @entity1442 @entity157
BACKGROUND: @entity157 ( @entity157 ) significantly contributes to the global burden of @entity5 . @entity96 is the third most frequent cause of @entity5 , with @entity157 representing more than 90% of primary @entity96 . During the last decade, much progress has been made with respect to the definition of @entity1 populations at risk who may benefit from surveillance strategies, as well as in the diagnosis and treatment of the disease. SUMMARY: New locoregional and systemic therapies have significantly increased the survival of @entity1 with @entity157 . A multitude of clinical trials addressing @entity1 with @entity157 have led to advancements in the allocation of subgroups of @entity1 to their optimal individual treatment strategy. This review provides an overview on recent developments in diagnostic and therapeutic modalities and an outlook on future directions in the management of @entity157 . KEY MESSAGE: New locoregional and systemic therapies in @entity1 with @entity157 have significantly improved clinical outlook and @entity1 survival. This review provides an overview of recent developments in diagnostics and therapeutics, as well as an outlook on future directions in the management of @entity157 . PRACTICAL IMPLICATIONS: Transabdominal ultrasound is the method of choice for the surveillance of @entity1 at risk of developing @entity157 , and any suspicious focal lesion in the liver should be characterized. Contrast-enhanced ultrasound with application of second-generation contrast agents enables visualization of @entity5 vascularity. The Barcelona Clinic @entity96 (BCLC) system is the most widely used classification system to guide the clinical management of @entity157 . Liver resection should be considered for @entity1 with well-preserved liver function and without portal @entity101 or elevated @entity648 . @entity1 not suitable for resection should undergo local @entity5 ablation. Candidates who are eligible for liver transplantation may benefit from bridging therapy during their waiting period. @entity1 in the BCLC B category benefit from locoregional transarterial therapy; transarterial chemoembolization is the treatment of choice. @entity2857 is the only systemic therapy that has been shown to prolong overall survival in @entity1 with @entity1442 , and is therefore recommended in @entity1 with well-preserved liver function.
